Dublin, Ireland - Insurers will benefit from a trend in wide-spread adoption of electronic capture of patient data, according to Research and Markets, Dublin, Ireland. In a newly released report, Research and Markets says many businesses already routinely capture documents and data for both regulatory and business intelligence purposes. But health care in the clinical setting has resisted this industry-transforming technology for nearly 20 years, citing the lack of user-friendly interfaces for busy health care providers, lack of workflow understanding on the part of vendors, the expense and complexity of implementation and maintenance solutions, and, simply, the lack of a transparent return on investment for providers. Research and Markets addresses this in "How Electronic Data Capture Will Change Healthcare and Pharmaceutical Marketing," an addition to its offerings of market research reports and industry newsletters.
Both health care providers and biopharmaceutical companies will likely be swept up in the coming change, according to Research and Markets. In a world where health information can be captured, measured, shared and compared, patient health outcomes information will become a paramount form of business intelligence.
Capture and analysis of heretofore unavailable data will provide outcomes data that will allow constant post-marketing surveillance, not just by the pharmaceuticals but also by insurers, caregivers and the public, says the report. Data capture will identify changing patient treatment populations, bringing new opportunities in R&D and in targeted marketing. Health data capture will feed into the growing consumer-directed health care movement, resulting in greater patient advocacy and awareness.
The following business implications are just a few discussed in Research and Markets' Decision Resources report:
-- The ability to electronically capture patient health data and information will be widely supported by insurers to support pay-for-performance policies advocated by Medicare.
-- Through the formation of a national health information network, treatment and outcomes will be measurable on a local, regional and national level.
-- Reimbursement policy and drug, device and procedure pricing will be determined by the U.S. Centers for Medicare & Medicaid Services and payers based on health economics driven by measurable outcomes.
Topics covered in the report include:
-- Electronic Data Capture: The Adoption Challenge
-- EHR: A Brief History and Status Report
-- Toward a National Health Information Network
-- The Power of Aggregated Data
-- Have We Reached the Tipping Point?
-- The Advantages of EHR Adoption for Biopharma
Source: Research and Markets
